A new review article has highlighted the crucial role of GATA6, a transcription factor, in pancreatic ductal adenocarcinoma (PDA).

The article published in Genes & Diseases explores GATA6’s dual role in cancer progression and its potential as a biomarker and treatment target.

Pancreatic cancer remains one of the deadliest malignancies, with a five-year survival rate of only 5%.

This study finds that higher GATA6 expression correlates with better tumour differentiation and improved patient outcomes, while low GATA6 levels are linked to aggressive basal-like PDA, a chemotherapy-resistant subtype.

It is also revealed that GATA6 influences multiple cancer-related pathways—including Wnt, Notch, Hedgehog, TGF-β, and VEGFR—helping to regulate tumour development.

While GATA6 overexpression can promote cancer growth, it also helps maintain epithelial differentiation, preventing tumour dedifferentiation and metastasis.

The authors suggest that GATA6 could serve as a biomarker for distinguishing PDA subtypes.

Patients with low GATA6 expression are more likely to have treatment-resistant basal-like PDA, indicating a need for alternative therapies.

Notably, the findings suggest that GATA6-deficient tumours respond poorly to chemotherapy (such as FOLFIRINOX) but may benefit from targeted therapies involving the EGFR pathway.

These insights could lead to more personalised treatment strategies, improving survival rates.

With pancreatic cancer accounting for 7% of all cancer-related deaths, this research advances the understanding of PDA progression and treatment response.

The study underscores the need for further clinical trials to validate GATA6’s potential as a predictive biomarker and treatment target, paving the way for more effective precision medicine approaches.

Source: Compuscript Ltd